WCM
ALNY icon

Wealthcare Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Wealthcare Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-15
Closed -$2K – 261
2019
Q4 		$2K Buy
+15
New +$1.5K ﹤0.01% 387

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wealthcare Capital Management's ALNY Position: Q1 2020 in Review

Wealthcare Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2020, closing a stake of 15 shares — an estimated $2K sold.

Wealthcare Capital Management first reported a position in ALNY in Q4 2019 and held it in 1 quarter. The position peaked at $2K in Q4 2019. 330 funds tracked by Wall St. Rank hold ALNY as of Q1 2020.

  • Wealthcare Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Wealthcare Capital Management sold 15 Alnylam Pharmaceuticals shares in Q1 2020, an estimated $2K.
  • Wealthcare Capital Management first reported a position in Alnylam Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Wealthcare Capital Management's Alnylam Pharmaceuticals position peaked at $2K in Q4 2019.
  • 330 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2020.

Based on Wealthcare Capital Management's 13F filing for Q1 2020, filed 29 Apr 2020.